These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31197750)

  • 1. The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Neth Heart J; 2019 Nov; 27(11):541-549. PubMed ID: 31197750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry.
    Capranzano P; Capodanno D; Brugaletta S; Latib A; Mehilli J; Nef H; Gori T; Lesiak M; Geraci S; Pyxaras S; Mattesini A; Münzel T; Araszkiewicz A; Caramanno G; Naber C; Di Mario C; Sabatè M; Colombo A; Wiebe J; Tamburino C
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):444-453. PubMed ID: 29068130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS.
    Hommels TM; Hermanides RS; Berta B; Fabris E; De Luca G; Ploumen EH; von Birgelen C; Kedhi E
    Cardiovasc Diabetol; 2020 Oct; 19(1):165. PubMed ID: 33008407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
    Kerkmeijer LSM; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Kraak RP; Onuma Y; Serruys PW; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):713-720. PubMed ID: 33118696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
    Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
    Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≤18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R).
    Zaczkiewicz M; Wein B; Graf M; Zimmermann O; Kastner J; Wöhrle J; Thomas R; Hamm C; Torzewski J;
    Int J Cardiol Heart Vasc; 2020 Apr; 27():100501. PubMed ID: 32258361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial.
    Xu B; Yang Y; Han Y; Huo Y; Wang L; Qi X; Li J; Chen Y; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Popma JJ; Gao R; Stone GW
    EuroIntervention; 2018 Aug; 14(5):e554-e561. PubMed ID: 30082268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.
    Chang CC; Onuma Y; Achenbach S; Barbato E; Chevalier B; Cook S; Dudek D; Escaned J; Gori T; Kočka V; Tarantini G; West NEJ; Morice MC; Tijssen JGP; van Geuns RJ; Smits PC;
    Cardiovasc Revasc Med; 2019 Jul; 20(7):577-582. PubMed ID: 31153846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
    Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C
    EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials.
    Stone GW; Abizaid A; Onuma Y; Seth A; Gao R; Ormiston J; Kimura T; Chevalier B; Ben-Yehuda O; Dressler O; McAndrew T; Ellis SG; Kereiakes DJ; Serruys PW
    J Am Coll Cardiol; 2017 Dec; 70(23):2863-2874. PubMed ID: 29100704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry.
    Lhermusier T; Carrie D; Cayla G; Fajadet J; Sainsous J; Elhadad S; Tarragano F; Chevalier B; Ranc S; Curinier C; Le Breton H; Koning R;
    Catheter Cardiovasc Interv; 2021 Sep; 98(3):511-519. PubMed ID: 33211387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three to four years outcomes of the absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: A meta-analysis.
    Goel S; Pasam RT; Chava S; Sharma A; Malik BA; Ayzenberg S; Frankel R; Shani J; Gidwani U
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):216-223. PubMed ID: 31002216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials.
    Jackson-Smith E; Zioupos S; Banerjee P
    Open Heart; 2022 Oct; 9(2):. PubMed ID: 36288820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.
    Kereiakes DJ; Ellis SG; Metzger C; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
    J Am Coll Cardiol; 2017 Dec; 70(23):2852-2862. PubMed ID: 29100702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience.
    Costopoulos C; Crowson MC; Brown AJ; Braganza DM; Bennett MR; Hoole SP; West NE
    Cardiovasc Revasc Med; 2015 Dec; 16(8):461-4. PubMed ID: 26440767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.